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analysis was performed on real-world observational data from the years 2010-2013 
in The Netherlands. Data on use and adherence was collected, in patients who were 
dispensed bupropion or varenicline in community pharmacies for the first time. 
Adherence was defined a using minimal 80% of the in guidelines recommended 
duration and intensity of use. Results: The study cohort consisted of 4,412 users of 
pSCT. The number of prescriptions was stable at 0.5 prescriptions per 1,000 inhabit-
ants (dispensing prevalence, dp) during 2010. The prevalence was on average 0.8 
dp, with peaks in the the 1st and 4th quarters of 2011. In 2012, the prevalence was 
stable at 0.4 dp. In 2013 was on average 0.5 dp, with a small peak in the 1st quarter. 
Adherence was 18% in 2010 and 2012 (non-reimbursement period), and 21% in 2011 
and 2013 (reimbursement period). ConClusions: Not only the likelihood of start-
ing smoking cessation, but also the extent of adherence to pharmacologic smoking 
cessation is higher during reimbursement. Increasing the awareness of health care 
providers on adherence issues is warranted.
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objeCtives: Exacerbations are considered one of the main drivers of costs of 
Chronic Obstructive Pulmonary Disease (COPD). In moderate to severe COPD 
patients with a history of exacerbations, the addition of an inhaled corticosteroid 
(ICS) to a long acting β 2 agonist (LABA) has been associated with a decreased rate of 
exacerbations versus treatment with LABA alone. This study aims to estimate the 
health care costs that the addition of the ICS Fluticasone Furoate (FF) to the LABA 
vilanterol (VI) could avoid versus LABA monotherapy in Spanish patients due to 
the reduction of the rate of exacerbations. Methods: The number of moderate 
to severe COPD patients > 40 years old with a history of exacerbation potentially 
treated with FF+VI was estimated from Spanish prevalence data. 1-year Monte-Carlo 
simulations (one simulation per patient) were developed to simulate the number of 
moderate and severe exacerbations and the health care costs avoided with FF+VI 
versus VI from the National Health System (NHS) perspective. Monte-Carlo simula-
tion was chosen as it allows simulating the effect of changes in different param-
eters obtained from clinical studies to describe real-life distributions. Parameters 
used in the simulations were the yearly rate of moderate-severe exacerbations 
with FF+VI and VI obtained from pooled-analysis of two head-to-head clinical trials 
(NCT01009463 and NCT01017952) and the costs of moderate and severe exacerba-
tions obtained from an observational study in real-life Spanish setting. Results: 
18,098 patients were included. FF+VI could avoid 7,424 moderate and severe exac-
erbations (95% confidence interval 7,411; 7,438) vs VI. The reduction in the number 
of exacerbations could lead to average health care costs avoided to the NHS of 3,278, 
382€ (3,066, 703€ ; 3,336, 392€ ) in a year. ConClusions: Treatment with FF+VI could 
decrease the economic burden associated with COPD reducing the health care costs 
for the Spanish NHS due to the decreased rate of exacerbations compared with 
LABA (VI) monotherapy.
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objeCtives: Data of british specialists show, that 5-11 out of 1000 adults have com-
munity-acquired pneumonia (CAP) every year, which is 5-12% of all cases of lower 
respiratory tract infections. The rate of CAP took over 3% in the structure of total 
respiratory organs disease rate in Ukraine within years 2007-2011. Methods: The 
data of use of antimicrobial preparations (AP): cephalosporins (ceftriaxone), penicil-
lins (amoxicillin and enzyme inhibitor), macrolides (azithromycin) and fluoroqui-
nolones (ciprofloxacin, levofloxacin) for CAP treatment in Kharkiv hospital were 
used. Analysis of affordability as of index of payment capacity (Ca. s.) of trade names 
(TNs) provided in pharmaceutical market of Ukraine on indicated INN has been 
carried out to determine the availability of such preparations for wider population 
of Ukraine. Results: Results of the AP affordability analysis made in five groups of 
INN, showed, that the ratio of therapy of high, middle and low availability for each 
AP group is different, but in all pharmacological groups except for ceftriaxone group, 
highly available therapy prevails. Percentage of highly available preparations in the 
studied groups of INN is: azitromycin (92.2%) > ciprofloxacin (74.3%) > amoxicillin 
and enzyme inhibitor (67.5%) > ceftriaxone (49.02%) > levofloxacin (46.94 %). As of 
preparations of middle availability, costing 5% - 15% of average monthly salary, cef-
triaxone preparations are most (49.02%), azitromycin preparations are least (6.49%). 
There are no low availability preparations in ciprofloxacin fluoroquinolone group. 
Cephalosporins and macrolides group preparations have one AP of low availability. 
Pharmacotherapy with application of preparations-analogous to levofloxacin, is 
costly, as 32.7% of preparations of this group are preparations of low availability 
(16 AP). ConClusions: Antibacterial preparations needed for treatment of CAP 
are present in the pharmaceutical market of Ukraine in wide range of preparations 
and cost. It makes them available to various social groups.
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objeCtives: Though tobacco price increases are effective in reducing tobacco con-
sumption and prevalence of smoking, tobacco-tax in Japan is still lower than those in 
other developed countries. General public, particularly non-smokers, may think that 
inflammatory formulations were discontinued during 12 months after asthma diag-
nosis. ConClusions: Asthma treatment utilization patterns reflect poor asthma 
control among newly diagnosed elderly patients, and initiation of anti-inflammatory 
treatment after asthma diagnosis appears to be inconsistent with asthma manage-
ment guidelines.
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objeCtives: The primary objective of this study was to examine the accuracy of 
the GOLD 2011 strategy implementation among the Czech respiratory specialists, 
esp. with respect to the patients’ classification. The secondary objective was to 
explore what effect a misclassification has on inadequate use of inhaled corticos-
teroids (ICS). Methods: Multicentre cross-sectional study was conducted among 
COPD specialists, consisting of general questionnaire and patient-specific forms. A 
subjective classification into the GOLD 2011 groups as practiced by the health care 
professionals was examined and then compared with the objective classification 
achieved by rigorous software-computed classification. Adequacy of the ICS pre-
scription was evaluated with regard to the subjective classification. Results: GOLD 
2011 were claimed to be the leading guidelines for 143 out of 144 specialists involved, 
often accompanied by CPPS guidelines (83.3%) and the ACP/ACCP/ATS/ERS standards 
(50.7%). Based on 1355 patient forms, a discrepancy between the subjective and 
objective classification was found in 32.8% of cases. The most common reason for 
incorrect classification was erroneous symptoms assessment resulting in either 
under-estimation in 23.9% of cases and over-estimation in 8.9% of the examined 
patients’ records. Specialists seeing more than 120 patients per month were most 
likely to misclassify their condition, i. e. in 36.7% of all seen patients. In general, 
whilst examining the subjectively-driven ICS prescription, it was found that 19.5% 
of patients received ICS incorrectly, while in 12.2% of cases the ICS was erroneously 
omitted. Furthermore, with consideration to the objectively computed classifica-
tion, it was discovered that 15.4% received ICS unnecessarily, whereas in 15.8% of 
cases the ICS was not prescribed though, in fact, it would be adequate seeing the 
patient’s condition. Women failed in correct prescription more frequently than men, 
predominantly by overprescribing ICS. ConClusions: Despite high awareness of 
the GOLD 2011 guidelines, its implementation is insufficient. Czech specialists tend 
to either under-classify or overuse the ICS.
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objeCtives: Twitter, a popular social media outlet, has become a useful tool for 
the study of social behavior through user interactions called tweets. The location 
time, and message content of tweets provide invaluable social and demographic 
information for an applied comparison of social behaviors across the world. Our 
goal is to determine the density and sentiment surrounding tobacco and e-cigarette 
tweets and link prevalence of word choices to tobacco and e-cigarette use at various 
localities. Methods: All tweets with geo-spatial coordinates are salvaged from the 
twitter-feed, representing approximately 1% of the entire twitter-sphere. Pattern 
matching by tobacco and e-cigarette related keywords yield approximately 20,000 
affiliated tweets per month from North America. The emotionally charged words 
that contribute to the positivity of various subsets of regional tweets are quantita-
tively measured using hedonometrics. We examined the density of these behavioral 
tweet indicators by region and tested the relationship between tweeted smoking 
sentiments and time-space-type coordinates over a 4-month span. Results: For 
states with ≥ 600 tobacco related tweets (N= 30), we find a strong positive correla-
tion (Pearson’s r= 0.54, p< 0.01) between the relative tweet density per state and 
the average positivity of tobacco related tweets. However, state-to-state sentiment 
comparisons suggest the attitude toward tobacco use can vary. We also explore 
the relationship between the ratio of tobacco tweets per state-to-state smoking 
rate estimates. Our results illustrate significant variation in smoking sentiments 
by state and at varying regional scopes. ConClusions: It is anticipated that real-
time analysis of nicotine and tobacco products using tweets will allow for more 
targeted forms of health policy planning and intervention. Regional density of 
nicotine and tobacco use related tweets yield insight to the prevalence of tobacco 
usage per capita. Sentiment analysis across the twitter-sphere can help illuminate 
hazardous health behavioral trends, which may lead to better targeting of health 
behavior interventions.
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bACkgRound: The discussion on the reimbursement of Smoking Cessation 
Treatment (SCT) has known many stages in The Netherlands. From January 2011, 
SCTs were reimbursed, until January 2012 when the reimbursement of nicotine 
replacement therapies (NRTs) and pharmacotherapeutic SCT (pSCT) was discon-
tinued. As of 2013, NRTs and pSCTs were again reimbursed for a maximum of one 
attempt per calendar year, provided they are accompanied by behavioural coun-
selling. objeCtives: To assess the impact of changes in reimbursement policy 
of pSCT on use and adherence. Methods: A retrospective dispensing database 
